Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
71 participants
INTERVENTIONAL
2013-02-28
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurosteroids in PTSD - Biomarkers to Therapeutics
NCT03491007
Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)
NCT01477762
Ketamine-enhanced Prolonged Exposure Therapy in PTSD
NCT04560660
Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics
NCT03947099
Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD
NCT01090180
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Group
Placebo Comparator
Placebo
Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
Drug group
7 Keto-DHEA
7-Keto Dehydroepiandrosterone
7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
7-Keto Dehydroepiandrosterone
7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
Placebo
Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages 18-64
* Primary diagnosis of PTSD as assess by the clinician administered PTSD scale and independent clinical mental health evaluation
Exclusion Criteria
* Dementia
* Active alcohol and/or substance abuse or dependence
* Active suicidal or homicidal ideation
* Medical concerns that would exclude use of 7-Keto DHEA
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Humanetics Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alina Gonzalez-Mayo, MD
Role: PRINCIPAL_INVESTIGATOR
Bay Pines VAHCS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bay Pines VA Healthcare System
Bay Pines, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2905
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.